Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 5,341,433	$ 11,437,118
Supplies for clinical trials	1,302,206	1,186,186
Other assets	494,188	791,485
Total current assets	7,137,827	13,414,789
Property and equipment, net	93,228	109,823
Supplies for clinical trials	1,138,347	1,309,648
Deposits	1,920,894	1,955,514
Deferred financing costs	216,425	100,216
Total assets	10,506,721	16,889,990
Current liabilities:
Accounts payable	914,573	1,342,126
Accrued compensation and benefits	234,102	1,109,864
Accrued liabilities	1,010,137	786,953
Total current liabilities	2,158,812	3,238,943
CIRM liability	7,398,400	6,945,741
Warrant liability	470,784	573,560
Total liabilities	10,027,996	10,758,244
Commitments and contingencies (Note 5)
Shareholders’ equity:
Preferred stock $0.0001 par value, 1,000,000 shares authorized; 0 shares outstanding as of March 31, 2017 and December 31, 2016	0	0
Common stock, $0.0001 par value; 25,000,000 shares authorized; 3,449,075 and 3,444,859 shares issued and outstanding as of March 31, 2017 and December 31, 2016, respectively	345	344
Additional paid-in capital	102,526,809	102,354,844
Accumulated deficit	(102,048,429)	(96,223,442)
Total shareholders’ equity	478,725	6,131,746
Total liabilities and shareholders’ equity	$ 10,506,721	$ 16,889,990